Complementary studies of the gastrointestinal safety of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxib

• Published in: Alimentary pharmacology & therapeutics Vol. 17; no. 2; pp. 201 - 210
• Main Authors: Hunt, R. H., Harper, S., Callegari, P., Yu, C., Quan, H., Evans, J., James, C., Bowen, B., Rashid, F.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.01.2003; Blackwell
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid - drug therapy; Biological and medical sciences; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors - adverse effects; Double-Blind Method; Duodenal Ulcer - chemically induced; Etoricoxib; Female; Gastrointestinal Hemorrhage - chemically induced; Humans; Ibuprofen - adverse effects; Isoenzymes - antagonists & inhibitors; Male; Medical sciences; Membrane Proteins; Middle Aged; Occult Blood; Osteoarthritis - drug therapy; Prostaglandin-Endoperoxide Synthases; Pyridines - adverse effects; Stomach Ulcer - chemically induced; Sulfones - adverse effects

Summary Background : Cyclo‐oxygenase‐2‐selective non‐steroidal anti‐inflammatory drugs are intended to preserve cyclo‐oxygenase‐1‐mediated gastroprotection and platelet function, whilst inhibiting cyclo‐oxygenase‐2‐mediated inflammation. Aim : To assess the gastrointestinal safety of the cyclo‐oxyge...